Orris

Instructions: READ THE SITUATION AND GIVE DETAILED ANSWERS TO THE QUESTIONS A 58-year-old patient came to the clinic with complaints of weakness, a decrease in the volume of urine excreted, swelling in the legs, and an increase in blood pressure during the last two days. From the previous medical history, it is known that 2 days before going to the clinic, the patient was discharged from the hospital, where, due to stable coronary artery disease, angina, IV functional class, refractory to drug therapy, coronary angiography and stenting of the anterior descending and right coronary arteries were performed. At discharge, the condition was satisfactory; in routine lab tests all indicators were within the normative/target range. On echocardiography, LV EF is 55%. It is also known that the patient has type 2 diabetes mellitus with previously adequate glucose control (glycated hemoglobin 7.1%) and hypertension for more than 10 years (previously achieved a stable target level of BP <130/80 mm Hg), and symptoms of chronic heart failure corresponded to II FC (NYHA). Currently taking aspirin 75 mg/day regularly, clopidogrel 75 mg/day, metoprolol succinate 25 mg/day, ramipril 5 mg/day, atorvastatin 80 mg/day, metformin 500 mg/day. Thus, 5 days after stenting of the coronary arteries, the patient noted an acute decrease in urinating (less than 100 ml over the last two days), the appearance of edema in the legs and an increase in blood pressure of more than 160/100 mm Hg, which persisted against the background of additionally taken moxonidine 40 mg and captopril 25 mg. On examination, the state of moderate severity, the skin is pale, dry, swelling of the feet, legs. BMI is 35.2 rg/m2. BP is 160/110 mmHg, Pulse is 50 beats / min. Heart sounds are soft, accent of the 2nd sound on the pulmonary artery, no murmurs. RR is 20 per minute. No rales are heard in the lungs. The abdomen is soft, painless on palpation. The liver and spleen are not enlarged. The symptom of tapping in the lumbar region is positive on both sides. In a biochemical blood test, creatinine is 589 µmol/l, urea is 50 mmol/l, potassium is 6.5 mmol/l. pH=7.19. Question 1. Make a preliminary diagnosis. Question 2. Justify your main diagnosis and complication of the main disease Question 3. Does the patient have life-threatening complications? Question 4. What is emergency care? Question 5. What are the outpatient preventive measures before a routine X-ray contrast study?

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Searching the Web

contrast induced nephropathy after coronary angiography stenting AKI management 2024 guidelines

I now have comprehensive information to provide detailed answers to all five questions. Let me compose the full response.

Clinical Case Analysis: 58-Year-Old Post-Coronary Stenting Patient with Acute Oliguria

Question 1: Preliminary Diagnosis

Main Diagnosis: Contrast-Induced Acute Kidney Injury (CI-AKI), Stage 3 (KDIGO criteria) - Oliguric form
Background diseases:
  • Coronary artery disease, stable angina (FC IV), status post coronary angiography with stenting of the LAD and RCA (5 days prior)
  • Type 2 Diabetes Mellitus, with adequate glycemic control (HbA1c 7.1%)
  • Hypertension, Stage 2 (uncontrolled, BP 160/110 mmHg)
  • Chronic Heart Failure, FC II (NYHA), preserved EF (55%)
  • Obesity, Class 2 (BMI 35.2)
Complications:
  1. Severe hyperkalemia (K⁺ 6.5 mmol/L) - life-threatening
  2. Metabolic acidosis (pH 7.19) - severe
  3. Uremic syndrome
  4. Hypertensive crisis (resistant/refractory type)
  5. Bilateral hydronephrosis (CVA tenderness positive bilaterally - may reflect renal edema/capsular tension from AKI)

Question 2: Justification of Main Diagnosis and Complications

Diagnosis Justification: CI-AKI Stage 3

The diagnosis of contrast-induced acute kidney injury is supported by the following reasoning:
Temporal relationship: The patient underwent coronary angiography with iodinated contrast medium 5 days prior. CI-AKI classically develops within 24-72 hours of contrast exposure, but in high-risk patients with multiple comorbidities, the peak creatinine rise and oliguric presentation can emerge later.
Risk factor burden (extremely high risk for CI-AKI):
  • Diabetes mellitus type 2 - diabetic patients with azotemia have ~38-51% incidence of CI-AKI after coronary angiography (Roberts and Hedges' Emergency Medicine)
  • Pre-existing cardiovascular disease with reduced cardiac output potential
  • Chronic heart failure (CHF FC II) - reduced effective renal perfusion
  • Hypertension >10 years - associated with nephrosclerosis / subclinical CKD
  • Obesity (BMI 35.2) - common association with hyperfiltration and renal vulnerability
  • Concomitant ACE inhibitor use (ramipril) - reduces renal perfusion pressure under stress
  • Concurrent metformin - further risks lactic acidosis when renal clearance falls
  • The procedure involved two-vessel stenting (LAD + RCA), implying a substantial volume of contrast media administered
Biochemical confirmation of AKI Stage 3:
  • Creatinine 589 µmol/L (6.67 mg/dL) - severe elevation indicating near-complete loss of GFR
  • Urea 50 mmol/L - consistent with uremia
  • This represents a creatinine increase of >3x from what was described as "within normal range" at discharge (~70-100 µmol/L baseline), meeting KDIGO Stage 3 criteria (>3-fold increase or creatinine ≥353.6 µmol/L)
Oliguric pattern: Urine output <100 mL over 2 days (virtual anuria) - meeting Stage 3 oliguria criteria (<0.3 mL/kg/hr for ≥24h or anuria ≥12h per KDIGO)
Clinical signs:
  • Bilateral CVA tenderness (tapping sign positive bilaterally) - capsular distension from renal edema
  • Bilateral leg edema - fluid overload from inability to excrete
  • Hypertensive crisis - loss of pressure natriuresis, fluid overload, activation of RAAS
  • Pale, dry skin - uremic facies

Complication Justification:

1. Severe Hyperkalemia (K⁺ = 6.5 mmol/L) Oliguric AKI dramatically impairs potassium excretion. At the same time, metabolic acidosis drives K⁺ out of cells (H⁺/K⁺ exchange). Both ramipril (ACE inhibitor) and the AKI itself suppress aldosterone-mediated kaliuresis. K⁺ 6.5 mmol/L is a life-threatening emergency requiring immediate intervention.
2. Severe Metabolic Acidosis (pH = 7.19) In AKI, the kidneys fail to excrete hydrogen ions and regenerate bicarbonate. The result is high-anion-gap metabolic acidosis (uremic acidosis). Additionally, metformin accumulation in the setting of renal failure raises concern for metformin-associated lactic acidosis (MALA) as a contributing factor, given that metformin is renally cleared and was continued through the post-procedure period. pH 7.19 is below the critical threshold of 7.20, necessitating active correction (Rosen's Emergency Medicine, Morgan & Mikhail's Clinical Anesthesiology).
3. Hypertensive Crisis (BP 160/110 mmHg, refractory) AKI causes sodium and water retention, volume overload, and RAAS activation. The patient's prior antihypertensives (metoprolol 25mg, ramipril 5mg) were insufficient, and even additional moxonidine + captopril failed to bring BP to target - consistent with volume-mediated, uremia-driven hypertensive crisis.
4. Uremic Syndrome Manifested by weakness, oliguria/anuria, edema, elevated urea (50 mmol/L) and creatinine - a toxic state resulting from accumulation of uremic solutes in the absence of effective renal excretion.
5. Bilateral obstructive hydronephrosis - to be excluded The bilateral positive CVA (costovertebral angle) tenderness is highly suspicious. In a post-procedural patient, bilateral obstruction (e.g., clot, contrast-precipitated crystals, uric acid) must be excluded by urgent renal ultrasound. If confirmed, this changes management (urgent urological drainage).

Question 3: Life-Threatening Complications

Yes, this patient has multiple concurrent life-threatening conditions:

1. Severe Hyperkalemia (K⁺ = 6.5 mmol/L) - IMMEDIATE THREAT

Potassium above 6.0-6.5 mmol/L carries a high risk of fatal cardiac arrhythmias (ventricular fibrillation, asystole). The mechanism: membrane depolarization reduces the threshold for action potential generation, causing myocardial excitability and conduction block. This is compounded by:
  • Concurrent metabolic acidosis (each 0.1 pH unit drop raises K⁺ by ~0.5 mmol/L)
  • Concurrent use of ramipril (reduces K⁺ excretion)
  • Pulse of 50 bpm (bradycardia) - possible early sign of cardiac hyperkalemia toxicity
An ECG should be obtained immediately to look for peaked T-waves, widened QRS, sine-wave pattern, or other signs of hyperkalemic cardiotoxicity.

2. Severe Metabolic Acidosis (pH = 7.19) - LIFE-THREATENING

pH < 7.20 is a medical emergency. Severe acidosis causes:
  • Myocardial depression and reduced cardiac contractility
  • Vasodilation and risk of circulatory collapse
  • Potentiates arrhythmias
  • CNS depression
  • Impairs cellular enzyme function

3. Acute Oliguric Renal Failure with Uremia - INDICATION FOR EMERGENCY RENAL REPLACEMENT THERAPY

With near-anuria (< 100 mL/48 hours), creatinine 589 µmol/L, and life-threatening hyperkalemia + acidosis, this patient meets emergent indications for hemodialysis:
  • Refractory hyperkalemia (AEIOU criteria: A = Acidosis, E = Electrolytes, I = Intoxication, O = Overload, U = Uremia)

4. Hypertensive Crisis (160/110 mmHg, refractory) in the Setting of Recent Coronary Stenting

Sustained elevated BP post-stenting risks:
  • Stent thrombosis
  • Acute coronary syndrome recurrence
  • Hypertensive encephalopathy or stroke

5. Possible Metformin-Associated Lactic Acidosis (MALA)

Metformin was continued into the post-procedure period. In established AKI with creatinine 589 µmol/L, metformin is severely accumulating. MALA carries ~50% mortality in susceptible patients (Campbell Walsh Wein Urology). The pH of 7.19 with near-anuria is consistent with this contributing cause.

Question 4: Emergency Care

Management must be immediate, simultaneous, and prioritized by life threat:

Step 1: Stabilization and Monitoring

  • Urgent 12-lead ECG - assess for hyperkalemic changes
  • Continuous cardiac monitoring (telemetry)
  • IV access (two large-bore cannulas)
  • Urinary catheter (Foley) - accurate urine output measurement, exclude urethral obstruction
  • Urgent renal ultrasound (Doppler) - exclude bilateral obstruction, assess kidney size and echogenicity
  • ABG (arterial blood gas) - confirm pH, pCO2, HCO3, lactate; check for MALA

Step 2: STOP and ADJUST Nephrotoxic/Dangerous Medications

  • Discontinue metformin IMMEDIATELY - MALA risk is severe; metformin is absolutely contraindicated in AKI
  • Discontinue ramipril (and captopril already taken) - ACE inhibitors reduce GFR and worsen hyperkalemia in AKI
  • Hold NSAIDs (none listed, but confirm)
  • Metoprolol succinate - can be continued cautiously (helps HR control, reduces myocardial oxygen demand), but monitor for bradycardia (HR already 50)
  • Atorvastatin - continue (renoprotective, beneficial post-stenting)
  • Aspirin + clopidogrel - continue (mandatory dual antiplatelet therapy within 30 days of stenting - stopping risks acute stent thrombosis)

Step 3: Treat Life-Threatening Hyperkalemia (K⁺ = 6.5 mmol/L)

Three-phase approach:
A. Cardiac membrane stabilization (immediate, within 2-5 minutes):
  • Calcium gluconate 10% - 10 mL IV over 2-5 minutes (or calcium chloride 3-5 mL 10%)
  • Repeat after 5 minutes if ECG changes persist
  • Works within minutes; protects heart but does NOT lower K⁺
B. Intracellular K⁺ shift (within 15-30 minutes):
  • Regular insulin 10 units IV + 50 mL of 50% dextrose (or 500 mL of 10% dextrose) - drives K⁺ intracellularly
  • Sodium bicarbonate 8.4% - 100-200 mEq IV over 30-60 min - also shifts K⁺ intracellularly AND corrects acidosis
  • Salbutamol (albuterol) nebulized 10-20 mg - β2-agonist stimulates Na/K-ATPase
C. K⁺ removal from the body:
  • Loop diuretic (furosemide IV) - if patient still has some urine output (trial: furosemide 80-200 mg IV); caution in near-anuria
  • Potassium-binding resin (patiromer or sodium zirconium cyclosilicate) - newer agents preferred over sodium polystyrene sulfonate
  • Hemodialysis - the definitive treatment for K⁺ removal in anuric/oliguric AKI (see below)
(Morgan & Mikhail's Clinical Anesthesiology; Rosen's Emergency Medicine; Goldman-Cecil Medicine)

Step 4: Treat Severe Metabolic Acidosis (pH 7.19)

  • Sodium bicarbonate IV - 100-150 mEq in 250-500 mL D5W infused over 1-2 hours
  • Target: raise pH > 7.20 (minimum safe target), ideally > 7.30
  • This simultaneously helps shift K⁺ intracellularly
  • Note: In AKI-associated acidosis, sodium bicarbonate has shown mortality benefit in patients with Stage 2-3 AKI and pH < 7.20 (Rosen's Emergency Medicine)

Step 5: Manage Fluid Balance

  • Fluid challenge cautiously - the patient has signs of volume overload (edema, hypertension). Aggressive hydration risks pulmonary edema
  • Goal: maintain euvolemia; do NOT give large NS boluses
  • If urine output does not respond to furosemide challenge, proceed directly to dialysis

Step 6: Blood Pressure Control

  • Avoid ACE inhibitors/ARBs (already holding ramipril/captopril)
  • IV antihypertensives: nicardipine infusion, labetalol IV, or hydralazine IV for controlled BP reduction
  • Target: reduce MAP by no more than 25% in the first hour (avoid rapid drops that could worsen renal perfusion)
  • Note: moxonidine use at this level of AKI is not recommended and should be stopped

Step 7: Emergency Renal Replacement Therapy (RRT/Hemodialysis)

Indications present in this patient (AEIOU criteria - ALL MET):
  • Acidosis - pH 7.19
  • Electrolytes - K⁺ 6.5 mmol/L (hyperkalemia refractory)
  • Overload - edema, anuria
  • Uremia - creatinine 589 µmol/L, urea 50 mmol/L, uremic syndrome
Action: Urgent nephrology consult, arrange emergency hemodialysis via temporary central venous catheter (internal jugular or femoral vein). This is the most effective treatment for all complications simultaneously.

Step 8: Treat Underlying Cause

  • CI-AKI is the most likely etiology - management is primarily supportive
  • Exclude bilateral obstruction by ultrasound - if present, urgent urology consult for nephrostomy/ureteric stent
  • If MALA confirmed by elevated lactate - dialysis is the treatment (removes metformin)

Question 5: Outpatient Preventive Measures Before a Routine X-Ray Contrast Study

This question addresses what should have been done BEFORE the coronary angiography (or what should be done in the future before any elective contrast study in high-risk patients). This patient had multiple identifiable risk factors that were not adequately mitigated.

Pre-procedure Risk Stratification

  • Calculate eGFR (MDRD or CKD-EPI formula) from baseline creatinine - patients with eGFR < 60 mL/min/1.73m² require preventive measures; those with eGFR < 30 mL/min/1.73m² are at highest risk
  • Identify all risk factors: diabetes, CKD, CHF, advanced age, dehydration, concurrent nephrotoxins
  • This patient had: diabetes + CHF + hypertension + obesity + ACE inhibitor + metformin = very high risk

1. Adequate Pre-Hydration (Most Evidence-Based Intervention)

Per the Canadian Association of Radiologists guidelines and clinical evidence (Roberts and Hedges' Emergency Medicine):
For elective procedures:
  • 0.9% Normal Saline at 1 mL/kg/hr for 12 hours BEFORE and 12 hours AFTER the procedure
  • Alternative: Isotonic sodium bicarbonate (154 mEq/L in D5W) - 3 mL/kg bolus over 1 hour before, then 1 mL/kg/hr for 6 hours after (provides additional antioxidant protection in the tubule)
For semi-urgent procedures:
  • 5 mL/kg bolus of normal saline over 1 hour before, then 1 mL/kg/hr for 12 hours after
Goal: Ensure adequate renal tubular flow to dilute and flush contrast; maintain urine output > 150 mL/hr during the procedure window.

2. Temporary Discontinuation of Metformin

Per the ACR and Campbell Walsh Wein guidelines:
  • In patients with AKI, CKD Stage IV/V (eGFR < 30), or undergoing arterial catheter studies: discontinue metformin at least 48 hours BEFORE the procedure
  • Restart only after 48 hours post-procedure and after renal function has been re-evaluated and confirmed to be stable
  • Rationale: Metformin is renally cleared; iodinated contrast can cause transient or sustained AKI, which then accumulates metformin to levels that precipitate lactic acidosis (mortality 50%)
  • In patients with eGFR ≥ 30 and no AKI: metformin does NOT need to be discontinued before IV contrast

3. Minimize Contrast Volume

  • Use the lowest effective volume of low-osmolar or iso-osmolar contrast agent (e.g., iodixanol, iopromide)
  • Iso-osmolar agents are less nephrotoxic than high-osmolar agents (Comprehensive Clinical Nephrology)
  • Consider staged procedures (not both vessels in one session) if technically feasible in very high-risk patients
  • Avoid repeat contrast studies within 48-72 hours

4. Withhold Nephrotoxic and Renally-Acting Medications 24-48 Hours Before

  • ACE inhibitors (ramipril) - evidence is debated, but many centers hold them 24-48 hours before cardiac catheterization (KDIGO does not mandate this, but withholding may reduce post-procedural creatinine rise per observational data)
  • ARBs - same rationale
  • Diuretics (if present) - avoid on the day of the procedure (may cause dehydration)
  • NSAIDs - discontinue; reduce renal prostaglandins, impair autoregulation

5. N-Acetylcysteine (NAC) - Optional, Debated

  • Oral NAC 600 mg twice daily for 24 hours before and 24 hours after the procedure was historically recommended and is low-risk
  • Current evidence is mixed (PRESERVE trial 2018 showed no benefit of NAC over IV saline in high-risk CKD patients)
  • Still considered reasonable as an adjunct given low cost and minimal side effects

6. Optimization of Hemodynamics and Comorbidities

  • Ensure BP is controlled before elective procedures
  • Optimize heart failure status (reduce volume overload, optimize cardiac output) - low cardiac output is a major risk factor for CI-AKI
  • Optimize blood glucose pre-procedure (hyperglycemia worsens ischemic renal injury)

7. Patient Counseling and Post-Procedure Monitoring

  • Patient should report any decrease in urine output, edema, or symptoms after the procedure
  • Post-procedure creatinine measurement at 24-48 hours in all high-risk patients
  • Ensure adequate oral hydration post-procedure

Summary Table of Preventive Measures:

MeasureActionTiming
IV hydration (NS 1 mL/kg/hr)Inpatient/outpatient pre-hydration12h before and after
Hold metforminDiscontinue for high-risk patients (eGFR <30 or AKI)48h before; restart after 48h if renal function stable
Hold ACE inhibitor/ARBConsider withholding in high-risk patients24-48h before
Hold diureticsAvoid dehydrationDay of procedure
Minimize contrast volumeLow/iso-osmolar agent, minimum volumeDuring procedure
NAC 600 mg PO BIDOptional adjunct24h before and 24h after
Post-procedure creatinineMonitor renal function24-48h after
Renal ultrasound (baseline)Assess pre-existing CKDPre-procedure
Key Sources:
  • Comprehensive Clinical Nephrology, 7th Ed. - Contrast-Induced Nephropathy
  • Roberts and Hedges' Clinical Procedures in Emergency Medicine - Prevention of CIN, Table 71.5
  • Campbell Walsh Wein Urology - Specific Contrast Considerations; Metformin guidelines
  • Rosen's Emergency Medicine - Hyperkalemia, Metabolic Acidosis, Sodium Bicarbonate Therapy
  • Morgan & Mikhail's Clinical Anesthesiology - Treatment of Hyperkalemia and AKI
  • Goldman-Cecil Medicine - Treatment of Complications of AKI
This is a shared conversation. Sign in to Orris to start your own chat.